These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24458012)

  • 1. The paradox of scientific excellence and the search for productivity in pharmaceutical research and development.
    Grasela TH; Slusser R
    Clin Pharmacol Ther; 2014 May; 95(5):521-7. PubMed ID: 24458012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accessing external innovation in drug discovery and development.
    Tufféry P
    Expert Opin Drug Discov; 2015 Jun; 10(6):579-89. PubMed ID: 25910932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development speed paradox: can increasing development speed reduce R&D productivity?
    Lendrem DW; Lendrem BC
    Drug Discov Today; 2014 Mar; 19(3):209-14. PubMed ID: 24051396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving R&D productivity of pharmaceutical companies through public-private partnership: experiences from the Innovative Medicines Initiative.
    Laverty H; Gunn M; Goldman M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):545-8. PubMed ID: 23136843
    [No Abstract]   [Full Text] [Related]  

  • 5. How should we support pharmaceutical innovation?
    Grootendorst P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Driving external chemistry optimization via operations management principles.
    Bi FC; Frost HN; Ling X; Perry DA; Sakata SK; Bailey S; Fobian YM; Sloan L; Wood A
    Drug Discov Today; 2014 Mar; 19(3):289-94. PubMed ID: 23973340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-centered drug discovery as the means to improved R&D productivity.
    Raoof AA; Aerssens J
    Drug Discov Today; 2015 Sep; 20(9):1044-8. PubMed ID: 25908579
    [No Abstract]   [Full Text] [Related]  

  • 8. Open-access public-private partnerships to enable drug discovery--new approaches.
    Müller S; Weigelt J
    IDrugs; 2010 Mar; 13(3):175-80. PubMed ID: 20191434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Innovative Medicines Initiative (IMI): a new opportunity for scientific collaboration between academia and industry at the European level.
    Kamel N; Compton C; Middelveld R; Higenbottam T; Dahlén SE
    Eur Respir J; 2008 May; 31(5):924-6. PubMed ID: 18448501
    [No Abstract]   [Full Text] [Related]  

  • 10. Outsourcing chemical synthesis in the drug discovery process.
    Festel G
    Drug Discov Today; 2011 Mar; 16(5-6):237-43. PubMed ID: 21262378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Models for open innovation in the pharmaceutical industry.
    Schuhmacher A; Germann PG; Trill H; Gassmann O
    Drug Discov Today; 2013 Dec; 18(23-24):1133-7. PubMed ID: 23892183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of quality, capacity, and productivity at Merck.
    Nathan J; Venkataraman R
    Hosp Mater Manage Q; 1999 Feb; 20(3):64-9. PubMed ID: 10345635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biopharma CRO industry in China: landscape and opportunities.
    Xia C; Gautam A
    Drug Discov Today; 2015 Jul; 20(7):794-8. PubMed ID: 25701282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organizing for innovation: towards successful translational research.
    West W; Nightingale P
    Trends Biotechnol; 2009 Oct; 27(10):558-61. PubMed ID: 19683820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development.
    Wetherington JD; Pfister M; Banfield C; Stone JA; Krishna R; Allerheiligen S; Grasela DM
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):31S-46S. PubMed ID: 20881215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Drug Discovery Portal: a resource to enhance drug discovery from academia.
    Clark RL; Johnston BF; Mackay SP; Breslin CJ; Robertson MN; Harvey AL
    Drug Discov Today; 2010 Aug; 15(15-16):679-83. PubMed ID: 20547242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research and development productivity map: visualization of industry status.
    Shimura H; Masuda S; Kimura H
    J Clin Pharm Ther; 2014 Apr; 39(2):175-80. PubMed ID: 24438433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. To measure is to know: an approach to CADD performance metrics.
    Loughney D; Claus BL; Johnson SR
    Drug Discov Today; 2011 Jul; 16(13-14):548-54. PubMed ID: 21605697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virtual pharmaceutical companies: collaborating flexibly in pharmaceutical development.
    Forster SP; Stegmaier J; Spycher R; Seeger S
    Drug Discov Today; 2014 Mar; 19(3):348-55. PubMed ID: 24291787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new application of value-stream mapping in new drug development: a case study within Novartis.
    Heinzen M; Mettler S; Coradi A; Boutellier R
    Drug Discov Today; 2015 Mar; 20(3):301-5. PubMed ID: 25448754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.